UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure–activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog

Bioorganic & medicinal chemistry letters, 2006-01, Vol.16 (2), p.288-292

2006

Volltextzugriff (PDF)

5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: Molecular modeling studies on binding contribution of 1-(5-methylsulfonyl)pyrid-2-yl and 4-nitrile

Bioorganic & medicinal chemistry letters, 2007-02, Vol.17 (4), p.1067-1072

2007

Volltextzugriff (PDF)

Synthesis and SAR of heteroaryl-phenyl-substituted pyrazole derivatives as highly selective and potent canine COX-2 inhibitors

Bioorganic & medicinal chemistry letters, 2006-04, Vol.16 (8), p.2076-2080

2006

Volltextzugriff (PDF)

5-Heteroatom-substituted pyrazoles as canine COX-2 inhibitors: Part 2. Structure–activity relationship studies of 5-alkylethers and 5-thioethers

Bioorganic & medicinal chemistry letters, 2006-03, Vol.16 (5), p.1202-1206

2006

Volltextzugriff (PDF)

Comparative structure–activity relationship studies of 1-(5-methylsulfonylpyrid-2-yl)-5-alkyl and (hetero)aryl triazoles and pyrazoles in canine COX inhibition

Bioorganic & medicinal chemistry, 2008-02, Vol.18 (3), p.1042-1045

2008

Volltextzugriff (PDF)

In vitro and in vivo profile of 5-[(4' -trifluoromethyl -biphenyl -2-carbonyl ) -amino]-1H -indole -2 -carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity

Bioorganic & medicinal chemistry letters, 2007-04, Vol.17 (7), p.1996-1999

2007

Volltextzugriff (PDF)

Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine

Bioorganic & medicinal chemistry letters, 2004-01, Vol.14 (1), p.95-98

2004

Volltextzugriff (PDF)

Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents

Bioorganic & medicinal chemistry letters, 2006-06, Vol.16 (11), p.3039-3042

2006

Volltextzugriff (PDF)

In vitro and in vivo profile of 2-(3-di-fluoromethyl-5-phenylpyrazol-1-yl)-5-methanesulfonylpyridine, a potent, selective, and orally active canine COX-2 inhibitor

Bioorganic & medicinal chemistry, 2005-03, Vol.13 (5), p.1805-1809

2005

Volltextzugriff (PDF)

Effects of omeprazole on healing of naturally-occurring gastric ulcers in Thoroughbred racehorses

Equine veterinary journal, 1997-11, Vol.29 (6), p.425-429

1997

Volltextzugriff (PDF)

Acquainting Veterinary Students with Careers in the Pharmaceutical Industry

Journal of veterinary medical education, 2007, Vol.34 (2), p.139-142

2007

Volltextzugriff (PDF)

In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1 H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity

Bioorganic & medicinal chemistry letters, 2007, Vol.17 (7), p.1996-1999

2007

Volltextzugriff (PDF)

Acquainting Veterinary Students with Careers in the Pharmaceutical Industry

Journal of veterinary medical education, 2007-01, Vol.34 (2), p.139

2007

Volltextzugriff (PDF)

Comparison of the antisecretory effects of omeprazole when administered intravenously, as acid-stable granules and as an oral paste in horses

Equine veterinary journal, 1999-04, Vol.31 (S29), p.54-58

1999

Volltextzugriff (PDF)

Pedunculated lipomas as a cause of intestinal obstruction in horses: 17 cases (1983-1990)

Journal of the American Veterinary Medical Association, 1992-10, Vol.201 (8), p.1249-1252

1992

Volltextzugriff (PDF)

Effects of antibiotic prophylaxis on postoperative complications after rumenotomy in cattle

Journal of the American Veterinary Medical Association, 1992-05, Vol.200 (9), p.1332-1335

1992

Volltextzugriff (PDF)

Bovine Esophageal Surgery

The Veterinary clinics of North America. Food animal practice, 1990-07, Vol.6 (2), p.359-369

Haven, Michelle L.

1990

Volltextzugriff (PDF)

Leiomyoma of the Small Colon in a Horse

Veterinary surgery, 1991-09, Vol.20 (5), p.320-322

1991

Volltextzugriff (PDF)

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Clinical cancer research, 2012-10, Vol.18 (20), p.5650-5661

2012

Volltextzugriff (PDF)

Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing

Journal of medicinal chemistry, 2011-12, Vol.54 (24), p.8328-8342

2011

Volltextzugriff (PDF)

Essentials of Sleep Medicine: A Practical Approach to Patients with Sleep Complaints

2nd ed. 2022

Volltextzugriff (PDF)

Prospects for Cure in Wilson Disease

OBM Genetics, 2018-08, Vol.2 (3), p.1-1

2018

Volltextzugriff (PDF)

Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts

Assay and drug development technologies, 2007-06, Vol.5 (3), p.391-402

2007

Volltextzugriff (PDF)

The Growing Risk of Zoonotic & Vector-Borne Diseases ConferenceAugust 30–31, 2015Kansas City Convention Center

Vector borne and zoonotic diseases (Larchmont, N.Y.), 2015-07, Vol.15 (7), p.453-460

2015

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(30)
Bücher
(1)

Sprache

Englisch
(31)
Japanisch
(4)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure–activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog

5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: Molecular modeling studies on binding contribution of 1-(5-methylsulfonyl)pyrid-2-yl and 4-nitrile

Synthesis and SAR of heteroaryl-phenyl-substituted pyrazole derivatives as highly selective and potent canine COX-2 inhibitors

5-Heteroatom-substituted pyrazoles as canine COX-2 inhibitors: Part 2. Structure–activity relationship studies of 5-alkylethers and 5-thioethers

Comparative structure–activity relationship studies of 1-(5-methylsulfonylpyrid-2-yl)-5-alkyl and (hetero)aryl triazoles and pyrazoles in canine COX inhibition

In vitro and in vivo profile of 5-[(4' -trifluoromethyl -biphenyl -2-carbonyl ) -amino]-1H -indole -2 -carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity

Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine

Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents

In vitro and in vivo profile of 2-(3-di-fluoromethyl-5-phenylpyrazol-1-yl)-5-methanesulfonylpyridine, a potent, selective, and orally active canine COX-2 inhibitor

Effects of omeprazole on healing of naturally-occurring gastric ulcers in Thoroughbred racehorses

Acquainting Veterinary Students with Careers in the Pharmaceutical Industry

In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1 H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity

Acquainting Veterinary Students with Careers in the Pharmaceutical Industry

Comparison of the antisecretory effects of omeprazole when administered intravenously, as acid-stable granules and as an oral paste in horses

Pedunculated lipomas as a cause of intestinal obstruction in horses: 17 cases (1983-1990)

Effects of antibiotic prophylaxis on postoperative complications after rumenotomy in cattle

Bovine Esophageal Surgery

Leiomyoma of the Small Colon in a Horse

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)‑5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)

Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing

Essentials of Sleep Medicine: A Practical Approach to Patients with Sleep Complaints

Prospects for Cure in Wilson Disease

Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts

The Growing Risk of Zoonotic & Vector-Borne Diseases ConferenceAugust 30–31, 2015Kansas City Convention Center

Suchergebnisse filtern